ATE215099T1 - Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie - Google Patents

Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie

Info

Publication number
ATE215099T1
ATE215099T1 AT98939713T AT98939713T ATE215099T1 AT E215099 T1 ATE215099 T1 AT E215099T1 AT 98939713 T AT98939713 T AT 98939713T AT 98939713 T AT98939713 T AT 98939713T AT E215099 T1 ATE215099 T1 AT E215099T1
Authority
AT
Austria
Prior art keywords
cationic polymers
gene therapy
negative charge
nucleic acids
therapeutic agents
Prior art date
Application number
AT98939713T
Other languages
English (en)
Inventor
Hanno V J Kolbe
Otmane Boussif
Thierry Delair
Laurent Veron
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9709209A external-priority patent/FR2766194A1/fr
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE215099T1 publication Critical patent/ATE215099T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT98939713T 1997-07-21 1998-07-20 Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie ATE215099T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9709209A FR2766194A1 (fr) 1997-07-21 1997-07-21 Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique
FR9715807A FR2766195A1 (fr) 1997-07-21 1997-12-12 Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique
PCT/FR1998/001581 WO1999005183A1 (fr) 1997-07-21 1998-07-20 Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique

Publications (1)

Publication Number Publication Date
ATE215099T1 true ATE215099T1 (de) 2002-04-15

Family

ID=26233691

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939713T ATE215099T1 (de) 1997-07-21 1998-07-20 Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie

Country Status (12)

Country Link
US (1) US6407178B1 (de)
EP (1) EP0998501B1 (de)
JP (1) JP2001510863A (de)
AT (1) ATE215099T1 (de)
AU (1) AU740392B2 (de)
CA (1) CA2297487A1 (de)
DE (1) DE69804463T2 (de)
DK (1) DK0998501T3 (de)
ES (1) ES2172180T3 (de)
FR (1) FR2766195A1 (de)
PT (1) PT998501E (de)
WO (1) WO1999005183A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134420A1 (en) * 2000-02-18 2003-07-17 Lollo Charles Peter Methods and compositions for gene delivery
WO2002032396A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
AU2002257145B2 (en) * 2001-04-18 2005-06-02 Genzyme Corporation Method for lowering serum glucose
AU2003240978A1 (en) * 2002-05-31 2003-12-19 Genteric, Inc. Multi-functional polyamines for delivery of biologically-active polynucleotides
US20040077888A1 (en) * 2002-05-31 2004-04-22 The Regents Of The University Of California Polyamine-mediated transfection
DE10310196A1 (de) * 2003-03-06 2004-09-23 Rina-Netzwerk Rna Technologien Gmbh Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
AU2004260935A1 (en) * 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20070176158A1 (en) * 2006-02-01 2007-08-02 Robinson Jeffery A Portable safety barrier
US8686129B2 (en) * 2007-03-20 2014-04-01 Agilent Technologies, Inc. Methods for the separation of biological molecules using sulfolane
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
CN101970012A (zh) * 2007-09-14 2011-02-09 日东电工株式会社 药物载体
US8722348B2 (en) * 2008-05-28 2014-05-13 Wayne State University Method and composition for a protein transduction technology and its applications
AU2015270888B2 (en) * 2008-05-28 2017-11-16 Wayne State University Method and composition for a protein transduction technology and its applications
CA2934065C (en) 2013-10-25 2023-05-09 Qurgen, Inc. Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3325472A (en) * 1964-06-18 1967-06-13 Mortimer D Sackler Polycyclohexose-polyoxyethyleneglycol suppository bases
JPS60106804A (ja) * 1983-11-15 1985-06-12 Nitto Boseki Co Ltd ポリアリルアミンから誘導される新規な機能性樹脂
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
SE467309B (sv) * 1990-10-22 1992-06-29 Berol Nobel Ab Hydrofiliserad fast yta, foerfarande foer dess framstaellning samt medel daerfoer
ATE159262T1 (de) * 1992-07-22 1997-11-15 Hoechst Ag Hydrophile zentren aufweisende polyvinylamin- derivate, verfahren zu ihrer herstellung sowie die verwendung der verbindungen als arzneimittel, wirkstoffträger und nahrungsmittelhilfsstoff
DK0580079T3 (da) * 1992-07-22 1997-06-30 Hoechst Ag Tværbundne, nitrogenholdige vinylcopolymerer, fremgangsmåde til deres fremstilling samt anvendelse af disse forbindelser
DE4227019A1 (de) * 1992-08-14 1994-02-17 Geckeler Kurt E Priv Doz Dr Herstellung und Modifikation von Materialien auf der Basis von Amino- oder Amidpolymeren
DE4322884A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Biologisch aktive Polymere
US5260385A (en) * 1992-11-02 1993-11-09 Director-General Of Agency Of Industrial Science And Technology Biguanide group-containing polyallylamine and method of producing same
CA2167920A1 (en) * 1993-07-23 1995-02-02 Abraham J. Domb Nonoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5629184A (en) * 1995-01-25 1997-05-13 Amgen Inc. Cationic copolymers of vinylamine and vinyl alcohol for the delivery of oligonucleotides

Also Published As

Publication number Publication date
ES2172180T3 (es) 2002-09-16
FR2766195A1 (fr) 1999-01-22
CA2297487A1 (fr) 1999-02-04
DE69804463T2 (de) 2002-10-10
US6407178B1 (en) 2002-06-18
AU740392B2 (en) 2001-11-01
US20020031763A1 (en) 2002-03-14
AU8813198A (en) 1999-02-16
EP0998501A1 (de) 2000-05-10
DE69804463D1 (de) 2002-05-02
JP2001510863A (ja) 2001-08-07
DK0998501T3 (da) 2002-07-01
PT998501E (pt) 2002-08-30
EP0998501B1 (de) 2002-03-27
WO1999005183A1 (fr) 1999-02-04

Similar Documents

Publication Publication Date Title
ATE215099T1 (de) Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie
ATE334664T1 (de) Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
MX9700270A (es) Composicion que contiene acidos nucleicos, preparacion y utilizacion.
DE69535576D1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
BR9810369A (pt) Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
ATE492644T1 (de) Transfer von mrna unter verwendung von polykationischen verbindungen
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
AU5161800A (en) Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
EP1017797A4 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
FI942075A0 (fi) Sappihappojohdannaisten tetratsolijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina
CA2284859A1 (en) Nucleic acid molecule for a human skeletal muscle-specific receptor
EP0689586A4 (de) Funktion und aktivität des viralen proteins r (vpr)
NZ500300A (en) Compositions containing N-(3,4-dimethoxycinnamoyl) anthranilic acid for the treatment of excessive proliferation of retinal pigment epithelial cells
SE9503117D0 (sv) Novel use of padlock probes
NO20011817D0 (no) Ionebytte-tumormålsöking (IETT)
BR9909044A (pt) Vetor de tranferência de ácidos nucleicos, composição, utilização de um vetor de tranferência de ácidos nucleicos, processos de transfecção de ácidos nucleicos nas células, e de tratamento de doenças, e, célula recombinante
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
ATE376840T1 (de) Gentherapeutika
WO2001044198A8 (de) Amphiphile chinolylpolyamine als transfermittel für biologisch aktive makromoleküle
ATE292174T1 (de) Gentransfer in humane lymphocyten mittels retroviraler scfv-zelltargeting vektoren
CA2250433A1 (en) Human dnase ii
BR9909350A (pt) Compostos, composição, utilização de um composto, e, processos para preparação dos compostos, para transferência de ácido nucleicos para as células e para tratamento de doenças por meio de administração de um ácido nucleico

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee